Showing posts with label Point of Care Molecular Diagnostics Market. Show all posts
Showing posts with label Point of Care Molecular Diagnostics Market. Show all posts

Thursday, 25 April 2019

Point of Care Molecular Diagnostics Market Growing at a CAGR of 14.7%

The global point of care molecular diagnostics market was valued at USD 632.5 Million in 2017 and is projected to reach USD 1,440.2 Million in 2023, at a CAGR of 14.7%



The scope of the study includes POC molecular diagnostics analyzers and assays that enable healthcare professionals in the detection of diseases through molecular technologies in point-of-care settings. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023.


The key players in the global Point of care molecular diagnostics market are, Roche Diagnostics (Switzerland), Biomerieux (France), Danaher (US), Abbott Laboratories (US), Quidel (US) and Meridian Bioscience (US).

Target Audience:

  • POC Molecular Diagnostics Manufacturers
  • Physicians
  • Research Institutes
  • Diagnostics Suppliers
  • Market Research and Consulting Firms
  • Regulatory Bodies
  • Venture Capitalists

The POC molecular diagnostics market is segmented into RT-PCR, INAAT, and others technologies. In 2018, the RT-PCR segment is expected to account for the largest share of the global POC molecular diagnostics market. 

The large share of this segment can be attributed to the growing use of RT-PCR in proteomics and genomics and access to portable, easy-to-use devices. In the last three years from 2015, more than 42 RT-PCR based products have been launched for various diseases.

Wednesday, 5 December 2018

Point of Care Molecular Diagnostics Market : Industry Growth and Opportunities-Global Forecast to 2023

Growth in the point-of-care (POC) molecular diagnostics market is mainly driven by factors such as the increasing worldwide prevalence of infectious diseases, rising focus on decentralized diagnostics, and the growing demand for CLIA-waived molecular POC tests.
Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023", published by MarketsandMarkets™





Global market is expected to reach 
USD 1440.2 Million by 2023 from USD 725.5 Million in 2018, at a CAGR of 14.7%.


By product, the assays & kits segment is expected to dominate the market in 2018 
On the basis of product & service, the market is broadly segmented into assays & kits, instruments/analyzers, software & services. The assays & kits segment is expected to hold the largest share of the market in 2018 and is also projected to grow at highest CAGR in the global POC Molecular Diagnostics Market during the forecast period. An increasing number of assays and kits in this market have been granted the CLIA-waived status, which defines that the product can be used for decentralized settings or nontraditional laboratories, including physicians' offices, emergency rooms, and health department clinics. As a result, their applications have increased, making them the largest segment.
RT-PCR technology segment is expected to account for largest share of the market in 2018 
On the basis of technology, the market is broadly segmented into RT-PCR, INAAT, and other technologies. The RT-PCR segment is expected to account for the largest share of the global POC Molecular Diagnostics Market in 2018. RT-PCR is a highly cost-effective and preferred technology for POC settings that allows for the concurrent monitoring of expression levels of multiple genetic messages. Such benefits are driving the growth of the RT PCR segment.
Based on application, the respiratory segment is expected to account for largest share of the market in 2018 
On the basis application, the market is broadly segmented into respiratory diseases, hospital-acquired infections (HAIs), sexually transmitted diseases (STDs), oncology, hepatitis, and other applications (meningococcal meningitis, malaria, herpes simplex virus, Ebola, Zika virus). The respiratory application segment is expected to account for the largest share of the global POC Molecular Diagnostics Market in 2018. Growth in this market can be attributed to the rising prevalence of influenza and TB and the rising demand for the early diagnosis and detection of these diseases, especially in emerging countries.
Based on end user, the physician offices segment is expected to account for largest share of the market in 2018 
On the basis of end users, the market is broadly segmented into physician offices, hospital EDs and ICUs, research institutes, and other end users. The physician offices segment is expected to hold the largest share of the market. This share can be attributed to the increased preference for CLIA-waived tests for influenza diagnostics and faster turnaround time of POC molecular assay tests.
North America is expected to dominate the POC Molecular Diagnostics Market in 2018 
In 2018, North America is expected to account for the largest share of the global POC Molecular Diagnostics Market. The growing prevalence of infectious diseases, increasing number of CLIA product approvals, and rising government initiatives to support the adoption of POC molecular diagnostics in this region are driving the market growth.
Some of the key players in the global POC Molecular Diagnostics Market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Biomerieux SA (France), and Danaher (US). Product development was the major strategy adopted by these major players to maintain their leadership position in the global POC Molecular Diagnostics Market.
Know more about the Point of Care Molecular Diagnostics Market: 

Wednesday, 3 October 2018

Point of Care Molecular Diagnostics Market : Segments, Key Players, Drivers, Trends and Industry Analysis, Forecast 2023

According to the new market research report " Point of Care Molecular Diagnostics Market by Product & Service (Assays, Kits, Analyzers, Software), Application (Respiratory Disease, Hospital Acquired Infection), Technology (RT-PCR, INAAT), End User (Physician Office, ICUS) - Global Forecast to 2023", published by MarketsandMarkets™,



the global point of care (POC) molecular diagnostics market is projected to reach USD 1440.2 million in 2023 from USD 725.5 million in 2018, at CAGR of 14.7%.

Don’t miss out on business opportunities in Point of Care Molecular Diagnostics Market 

Speak to our analyst and gain crucial industry insights that will help your business 

 POC molecular diagnostics are various point of care portable device and assays & kits used by healthcare professionals to detect and diagnose diseases in human samples such as serum, blood, throat swab, and stool.

In this report, the market has been categorized based on product & service, applications, technology, end user, and region.

Based on the applications, the market is segmented into respiratory diseases, hospital-acquired infections (HAIs), sexually transmitted diseases (STDs), oncology, hepatitis, and other applications (meningococcal meningitis, malaria, Herpes Simplex Virus, Ebola, Zika virus). The respiratory application segment is expected account for the largest share of the global POC molecular diagnostics market in 2018. This large share of this segment can be attributed to the rising prevalence of influenza A & B and increasing research investments by key players for other respiratory disease such as Strep A and TB. In addition to this, most of the FDA approved RT-PCR POC molecular diagnostics are focused on influenza disease.

Browse and in-depth TOC on " Point of Care Molecular Diagnostics Market  "

68 - Tables
23 - Figures
106 - Pages

View more detailed TOC @

The POC molecular diagnostics market is broadly segmented into instruments, assays & kits, and services & software based on the basis of product & service. Assays & kits segment is expected to account for the largest share of the global POC molecular diagnostics market and expected to register the highest CAGR during the forecast period. POC molecular diagnostic assays and kits are specially designed for points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts. POC molecular diagnostics assays and kits enable the early diagnosis of respiratory tract infections, women’s health and sexual health conditions and among others.

The POC molecular diagnostics market is segmented into RT-PCR, INAAT, and others technologies. In 2018, the RT-PCR segment is expected to account for the largest share of the global POC molecular diagnostics market. The large share of this segment can be attributed to the growing use of RT-PCR in proteomics and genomics and access to portable, easy-to-use devices. In the last three years from 2015, more than 42 RT-PCR based products have been launched for various diseases.

In 2018, North America is expected to account for the largest share of the global POC molecular diagnostics market. Growing prevalence of infectious diseases, increasing number of CLIA product approvals, and rising government initiatives are the major factors driving the growth of this market in North America. However, Asia Pacific is expected to grow at highest CAGR during forecast period.


The key players in the global POC molecular diagnostics market are Abbott Laboratories (US), Biomerieux (France), Danaher (US) Roche diagnostics (Switzerland), Meridian biosciences (US), Quidel (US). These players focus on organic strategies such as product launches & approvals, to sustain their growth in the POC molecular diagnostics market.

Browse Adjacent Markets @ Medical Devices Research Reports & Consulting

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441

Tuesday, 18 September 2018

A New Trend in Molecular Diagnostics - Point of Care Molecular Diagnostics

The global POC molecular diagnostics market is projected to reach USD 1440.2 million by 2023 from USD 725.5 million in 2018, at a CAGR of 14.7%.

Growth in the POC molecular diagnostics market is driven by the increasing worldwide prevalence of infectious diseases, rising focus on decentralized diagnostics, and the growing demand for CLIA-waived molecular POC tests. Growing R&D activities in molecular diagnostic testing and the increasing penetration of POC molecular diagnostic tests in China, India, and Brazil are also expected to provide a wide range of growth opportunities for players in the market.

Point of Care Molecular Diagnostics Market


In this report, the market is segmented by product & service, technology, application, end user, and region. On the basis of product & service, the global POC molecular diagnostics market is segmented into assays and kits, instruments, and software & services. The assay and kits segment is expected to be the fastest-growing segment of the POC molecular diagnostics market in 2018. An increasing number of assays and kits in this market have been granted the CLIA-waived status, which defines that the product can be used for decentralized settings or nontraditional laboratories, including physicians’ offices, emergency rooms, and health department clinics. As a result, their applications have increased, making them the largest segment.

Based on application, the POC molecular diagnostics market is segmented into respiratory diseases, hospital-acquired infections (HAIs), sexually transmitted diseases (STDs), oncology, hepatitis, and other applications. The oncology segment is expected to be the fastest growing market owing to the rising prevalence of cancer, and investments in cancer research across the globe.

By technology, the POC molecular diagnostics market is segmented into RT-PCR, INAAT, and others (DNA sequencing and microarrays). INAAT is expected to be the fastest growing technology during the forecast period due to the increasing popularity of INAAT for infectious diseases diagnosis.

Geographically, POC molecular diagnostics market is segmented into four major regions—North America, Europe, Asia Pacific, and Rest of the World. Asia Pacific is expected to be the fastest growing market. The key factors influencing the growth of this market include growing initiatives by market players, rising demand for influenza A/B tests, decentralized healthcare delivery systems, and increasing patient population base in this region.

Point of Care Molecular Diagnostics Market

Patient Portal Market Size, Market Growth Projection to 2023

The growth of the overall patient portals market can be contributed to the federal mandates like meaning use, growing patient centric appro...